

[View this email in your browser](#)



AMERICAN COLLEGE OF ALLERGY, ASTHMA & IMMUNOLOGY

ADVOCACY COUNCIL ALERT

Leadership of the Advocacy Council met with Noridian Healthcare Solutions (Noridian) - a Medicare Administrative Contractor (MAC) for practices in Alaska, American Samoa, Arizona, California, Guam, Hawaii, Idaho, Montana, Nevada, North Dakota, Northern Mariana Islands, Oregon, South Dakota, Utah, Washington (state), and Wyoming - and is pleased to announce that **Noridian has acknowledged that for purposes of CPT 95165, diluted doses are treated the same as maintenance doses and are paid for if reasonable and necessary.** *In other words, Noridian may cover and pay for allergy immunotherapy build-up doses.*

As we all know, allergen immunotherapy, administered through subcutaneous injections, is a proven clinically effective treatment for individuals with allergic rhinitis and allergic asthma. We explained, as we did with the [Palmetto MAC](#), that when a patient begins immunotherapy, he or she typically begins with very diluted doses, and their concentration gradually increases over time. CPT code 95165 describes “professional services for the supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses).” The Advocacy Council is in receipt of an email from Noridian recognizing that, with regard to CPT code 95165, “Noridian treats diluted doses for the purposes of build-up and maintenance dosing the same, as long as reasonable and necessary.”

However, it is important to note that Medicare has assigned medically unlikely edits (MUEs) of 30 units per day for CPT code 95165. The MUEs are the maximum unit(s) of service that could be reported for a single beneficiary on the same date of service for the vast majority of appropriately reported claims. Claims in excess of the MUE number of units are considered “medically

Noridian's policy applies only to practices in states for which Noridian is the MAC. Allergy practices that submit claims to MACs other than Noridian and Palmetto may not rely on this policy to bill for dilutions.

The Advocacy Council is working to get similar acknowledgments from the other MACs and will keep you informed of our progress. This work is part of our [Payer Education Campaign \(PEC\)](#) that focuses on halting allergen immunotherapy audits and claims denials.

We acknowledge the important work done in this effort in long-term partnership with the Advocacy Council by Ned DeLozier of The Allergy, Asthma, and Sinus Center and John Herzog of Kimbell & Associates. We also acknowledge the assistance of the California Medical Association. In addition, we'd like to thank Senator Marsha Blackburn and Senator Bill Cassidy, MD, for their assistance with CMS in this effort.

IMPORTANT: The information contained herein is provided for educational purposes only and should not be construed or relied upon as legal advice. If legal advice is required, you should seek the advice of your legal counsel.

The Advocacy Council – **ADVOCATING FOR ALLERGISTS AND THEIR PATIENTS.**

Connect with the [College](#)



Copyright © 2024 American College of Allergy, Asthma and Immunology, All rights reserved.

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#)